Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company’s shift toward branded GLP-1 weight-loss drugs pressured its margins and domestic sales.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice.
Or get in touch at support@businessoffashion.com
if you experience difficulties.
